Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Key Highlights
- ➤Lycia CEO Aetna Wun Trombley to present at Jefferies Global Healthcare Conference November 18
- ➤Presentation scheduled for 3:00 p.m. GMT in London
- ➤Lead candidates LCA-0061 and LCA-0321 target allergic and autoimmune diseases
Expert Statements
Aetna Wun Trombley, President and Chief Executive Officer of Lycia Therapeutics
“will present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 3:00 p.m. GMT”
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced that Aetna Wun Trombley, president and chief executive officer of Lycia, will present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 3:00 p.m. GMT.
A live webcast of the presentation may be accessed in the Investors section of the Lycia Therapeutics website at ir.lyciatx.com. A replay of the webcast will be available for approximately 60 days following the presentation.
Get started
Create a free account to read the full story.